These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30594050)

  • 21. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
    Glenn JR; White AE; Iyu D; Heptinstall S
    Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
    Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
    J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets.
    Harmon S; Inkielewicz-Stepniak I; Jones M; Ledwidge M; Santos-Martinez MJ; Medina C; Radomski MW; Gilmer JF
    J Pharm Pharmacol; 2012 Jan; 64(1):77-89. PubMed ID: 22150675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiplatelet effects of caffeic acid due to Ca(2＋) mobilizationinhibition via cAMP-dependent inositol-1, 4, 5-trisphosphate receptor phosphorylation.
    Lee DH; Kim HH; Cho HJ; Bae JS; Yu YB; Park HJ
    J Atheroscler Thromb; 2014; 21(1):23-37. PubMed ID: 24088646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benzodiazepine analogues inhibit arachidonate-induced aggregation and thromboxane synthesis in human platelets.
    Fonlupt P; Croset M; Lagarde M
    Br J Pharmacol; 1990 Dec; 101(4):920-4. PubMed ID: 1964822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of intracellular signaling events in ADP-induced platelet aggregation.
    Daniel JL; Dangelmaier C; Jin J; Kim YB; Kunapuli SP
    Thromb Haemost; 1999 Oct; 82(4):1322-6. PubMed ID: 10544922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
    Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
    Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological activity of acyl substituted 3-amino-5-methyl-1,4,5,7-tetrahydropyrazolo[3,4-b]pyridin-6-ones as potential hypnotic drugs.
    Falcó JL; Lloveras M; Buira I; Teixidó J; Borrell JI; Méndez E; Terencio J; Palomer A; Guglietta A
    Eur J Med Chem; 2005 Nov; 40(11):1179-87. PubMed ID: 16095764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y
    Gündüz D; Tanislav C; Sedding D; Parahuleva M; Santoso S; Troidl C; Hamm CW; Aslam M
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
    Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
    Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.
    Bryant J; Post JM; Alexander S; Wang YX; Kent L; Schirm S; Tseng JL; Subramanyam B; Buckman B; Islam I; Yuan S; Sullivan ME; Snider M; Morser J
    Thromb Res; 2008; 122(4):523-32. PubMed ID: 18495218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingosylphosphorylcholine, a naturally occurring lipid mediator, inhibits human platelet function.
    Altmann C; Meyer Zu Heringdorf D; Böyükbas D; Haude M; Jakobs KH; Michel MC
    Br J Pharmacol; 2003 Feb; 138(3):435-44. PubMed ID: 12569068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effects of aprosulate sodium, a novel anticoagulant, on platelet activation: possible mechanism for antiplatelet action.
    Sugidachi A; Breiter N; Ogawa T; Asai F; Koike H
    Thromb Haemost; 1996 Nov; 76(5):786-90. PubMed ID: 8950791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of chondroitin 4-sulphate as a receptor for polycation induced human platelet aggregation.
    Donato JL; Marcondes S; Antunes E; Nogueira MD; Nader HB; Dietrich CP; Rendu F; de Nucci G
    Br J Pharmacol; 1996 Dec; 119(7):1447-53. PubMed ID: 8968554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.